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In tro duc ti on
Autoimmune thyroiditis (AIT) is the most common thyroid
disorder in the pediatric age range. Both a goitrous (Hashimoto’s
thyroiditis) and a nongoitrous (atrophic thyroiditis, also called
primary myxedema) variant of AIT have been distinguished. In
pediatrics, the most common age at presentation is adolescence,
but the disease may occur at any time, rarely even in children under
one year of age (1). In the past decade, the application of molecular
biology has permitted an unparalleled insight into susceptibility
genes that predispose to the development of AIT and into its
complex immune pathophysiology.  Approximately 70% of disease
risk is related to genetic susceptibility with environmental factors
playing a role in triggering disease in susceptible individuals.  In this
brief review, current concepts about the immuno-pathogenesis and
molecular genetics of AIT as well as putative environmental
triggers will be discussed.  In addition, clinical aspects unique to the
pediatric age range will be reviewed. 
Immuno-pathogenesis of Autoimmune Thyroiditis 
Cellular İmmune Responses
Because of the importance of  T- cells in immune regulation,
much attention has focused on this lymphocyte subpopulation to
explain the breakdown in tolerance and the clinical manifestations
seen in autoimmune thyroid disease (AITD).  Consistent with their
playing a fundamental role, an increased proportion of activated T-
helper (Th) (CD4+) cells can be demonstrated in the circulation of a
majority of patients with AIT (2) and this is thought to lead to a
cascade of immune-mediated events. Lymphocytic infiltration of
the thyroid gland and organization into lymphoid follicles occur due
to the secretion of numerous chemokines that direct leukocyte
migration and to adhesion molecules that lead to cell attachment to
extracellular matrix proteins. These processes are accompanied by
the secretion of complement, cytokines and other soluble
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mediators that damage the thyrocyte and lead ultimately to cell
death by apoptosis (3).  It is of interest that not only ‘professional’
antigen-presenting cells (e.g., macrophages, dendritic cells) but
thyroid follicular cells themselves  play a crucial role in determining
disease progression by expressing major histocompatibility
complex (MHC) class II antigens (4) and secreting cytokines and
chemokines.  Goiter,  present in approximately two-thirds of
children with AIT, results from both cellular infiltration and thyroid
follicular cell proliferation, a consequence of the compensatory
increase in thyrotropin (TSH) that occurs in response to thyrocyte
dysfunction.  
To add further to the complexity, there are actually 2 types of
Th cells: Th1 and Th2, each with a different pattern of cytokine
production, effector function, chemokine receptors, and regulation
(5). Th1 cells subserve cell-mediated immune responses, while
Th2 cells are involved in antibody production.  It has been
postulated that in AIT, a defect in a specific T cell subpopulation,
termed regulatory T cells (Tregs),  results in some way in a change
in the thyroid microenvironment, leading to decreased inhibition of
Th1 cells and the overproduction of Th1 cytokines. 
Humoral İmmunity
In addition to cell-mediated immune mechanisms, AIT is
characterized by the secretion of antibodies (Abs) to a variety of
thyroid-specific antigens, most notably thyroglobulin (Tg), and
thyroid peroxidase (TPO) but also to a lesser extent the TSH
receptor, the sodium iodide symporter (NIS) (6) and most recently
pendrin (7).  Whether, and, if so, how antibody-mediated immune
mechanisms contribute to the initiation, progression or
pathogenesis of AIT remains unclear.  Nonetheless, measurement
of Abs to Tg and TPO is useful diagnostically as markers of
underlying autoimmunity, and TSH receptor Abs may modulate the
activity of the TSH receptor, thereby affecting thyroid function in a
subset of patients. The role of Abs to NIS or pendrin is not yet clear.
Antibodies to Thyroglobulin and Thyroid Peroxidase
Tg Abs are directed at Tg, the very large 660 kDA homodimeric
protein that serves as the storage form and precursor of thyroid
hormone. There is some evidence that Tg Abs in patients with AIT
are more restricted in their epitope specificity than in healthy
individuals, but the antigenic determinants recognized by Tg Abs
are not known (8). Post-translational modifications such as
iodination and glycosylation may play a role in Tg antigenicity (9).
TPO Abs recognize TPO, the key membrane-associated enzyme
on the apical surface of the thyrocyte that mediates the iodination
and coupling of iodotyrosines to form thyroid hormone (10). Both
cytotoxicity (e.g., activation of the complement cascade and
participation in Ab-dependent, cell-mediated cytotoxicity ) and TPO
Ab-mediated inhibition of TPO function have been reported in vitro,
but these effects do not appear to be important in vivo as indicated
by the failure of these Abs to affect fetal or neonatal thyroid
function when transmitted to the fetus. Like with Tg Abs, some
epitopic specificity of TPO Abs has been reported in patients with
AIT (11), the significance of which is unclear.
TSH Receptor Antibodies
Abs to the TSH receptor have been classified as stimulatory,
blocking and neutral Abs (12).  All varieties recognize specific linear
epitopes presented in a 3-dimensional conformation , but their
interaction differs subtly. Like other members of the G-coupled
receptor superfamily, the TSH receptor is composed of a large, N-
terminal ectodomain, 7-transmembrane-spanning regions and a
small intracytoplasmic tail.  Although initial studies suggested
separate epitopes for stimulatory Abs on the N-terminus and for
blocking Abs on the C-terminus of the ectodomain, recent
evidence suggests more overlap than previously thought (12).
Stimulatory Abs appear to be of limited heterogeneity, whereas
blocking Abs are not similarly restricted. 
Both blocking and stimulating TSH receptor Abs can be found
in some patients with AIT. The coexistence of stimulatory TSH
receptor Abs and AIT has been termed ‘Hashitoxicosis’.  In
contrast, blocking Abs may contribute to the severity of the
hypothyroidism by inhibiting TSH-induced cell proliferation and
hormonogenesis. In a recent study of children and adolescents,
TSH receptor blocking Abs were found in 17.8% of  patients with
severe hypothyroidism (defined as a serum TSH concentration
>20 mU/L). However, unlike in adults, they were found in goitrous
as well as nongoitrous patients and, when present in  high
concentrations, appeared to persist indefinitely (13).  These data
suggest that the presence of potent TSH receptor blocking Abs in
adolescent females may identify patients at risk of having babies
with transient congenital hypothyroidism in their future ages. 
Immunosusceptibility Genes
Like Graves disease (GD) with which it is closely associated,
AIT is a complex immune disorder that occurs in individuals with
an underlying genetic susceptibility. As many as 20-60
immunosusceptibility genes, each with small effect,  have been
postulated (14).  Some genes are involved in immune recognition
and/or response in general, while others are thyroid-specific;
certain genes are common to both AIT and GD, while others tend
to predominate only in GD (8,9). In this brief review, only those that
affect individuals with AIT will be discussed. These genes are
summarized in Table 1.
Immune Response Genes
Human leukocyte antigen (HLA): The MHC region encodes a
highly polymorphic region that includes the genes for the class I (A,
Tab le  1. Genes implicated in the pathogenesis of autoimmune thyroiditis 
Gene  Role 
Immune recognition/response 
HLA-DR Antigenic recognition
CTLA-4 Costimulatory molecule; 
down regulates T-cell activation
PTPN-22  Inhibits T-cell  signaling
Thyroid-specific
Thyroglobulin  Storage form, precursor of thyroxine B and C) and class II (DR, DP and DQ) HLA. As peptide antigens
are presented to T cells only when bound to HLA class II
molecules, the HLA haplotype plays a critical role in determining
which antigens will be recognized by the T-cell receptor and trigger
an immune response. Unlike with GD, no consistent HLA-
association has been identified in patients with AIT. Recently,
Menconi et al (15) sequenced the polymorphic exon 2 of the HLA-
DR gene in 94 patients with AIT and 149 controls. They identified
a four-amino acid haplotype (Tyr-26, Tyr-30, Gln-70, Lys-71) that
conferred an odds ratio of 3.73 irrespective of the HLA haplotype;
the single amino acid Lys-71 conferred an odds ratio of 2.98. These
investigators postulated that specific ‘pocket amino acid
signatures’ determine susceptibility to AIT by causing critical
structural changes that influence antigenic peptide binding and
presentation.
Cytotoxic T Lymphocyte Antigen-4
Cytotoxic T lymphocyte (CTLA)-4, a transmembrane protein of
the immunoglobulin superfamily, is an important costimulatory
molecule that downregulates T-cell activation by binding to the B7
molecules present on antigen-presenting cells and preventing the
second signal necessary for T-cell activation. Linkage of the CTLA-
4 region with thyroid autoantibody production in patients with and
without clinical thyroid disease has been demonstrated (16). This
suggests that additional factors must be required for the
development of a thyroid functional abnormality.
Protein Tyrosine Phosphatase-22
Protein tyrosine phosphatase 22 (PTPN22) encodes a protein,
lymphoid tyrosine phosphatase (LYP), which is a potent inhibitor of
the T-cell receptor signaling pathway . A tryptophan for arginine
substitution at codon 620 of the LYP molecule has been
associated with both GD and AIT in some but not all ethnic
populations (16).
Thyroid-specific Gene
The thyroid-specific genes that have been incriminated in AITD
include those that code for Tg and the TSH receptor, but only the
Tg  gene has been associated with AIT.
Thyroglobulin
Tg is a very large 660kDA homodimeric protein that functions
as the storage form and precursor of thyroid hormone. In
genetically susceptible mice, experimental AIT can be induced by
Tg immunization and there is evidence that Tg sensitization may
play a role in patients with AITD as well. Detailed sequence
analysis of the Tg gene has demonstrated significant associations
between specific polymorphisms of Tg SNPs and AIT (17,18).
These findings suggest that specific Tg polymorphisms might be
more optimally presented to T cells by specific HLA haplotypes,
thereby triggering an immune response. This is highly reminiscent
of findings in experimental animals in which induction of AIT is also
HLA-dependent. 
In addition, the immunogenicity of Tg has been related to the
extent of its iodination (19). The pathogenic mechanisms whereby
increased iodine predisposes to AIT remain unclear.
Environmental Factors
The precise environmental trigger(s) leading to the
development of disease is not known with certainty, but infection,
drugs (lithium, amiodarone, interferon-alpha), hormones
(estrogen), dietary substances (iodine, selenium), stress, smoking
and, most recently, environmental toxins have all been implicated
(20,21).  An epigenetic mechanism has been postulated in some
cases (21).  
Incidence and Associations
AIT is more common in North America and Japan than in
some iodine-deficient parts of Europe and there is a striking female
preponderance, even prior to puberty. AIT may occur alone or may
coexist with other organ-specific autoimmune diseases,
particularly type 1 diabetes mellitus (T1DM).  The combination of
AIT with specific autoimmune disorders has been termed the
autoimmune  polyglandular syndromes (APS).  APS 1, which tends
to present in the first decade of life and is caused by a mutation in
a single (‘autoimmune regulator’) gene, is characterized by the
sequential development of mucocutaneous candidiasis,
hypoparathyroidism and adrenal deficiency (22).  AIT is amongst a
multiplicity of other organ-specific diseases that can also develop
in a minority of affected patients. In   APS-2 which tends to present
later in childhood or adolescence, Addison’s disease is found in
association with AIT (Schmidt syndrome) or AIT plus T1DM
(Carpenter syndrome) (23). Multiple other organ-specific
autoimmune diseases may also be present.  AIT has also been
described in children with immunodysregulation
polyendocrinopathy enteropathy X-linked (IPEX) syndrome, a
polyglandular disorder characterized by early-onset diabetes and
colitis (24) . There is an increased incidence of AIT in patients with
certain chromosomal abnormalities [Down syndrome (25), Turner
syndrome (26), and, to a lesser extent, Klinefelter syndrome] as
well as in patients with Noonan syndrome. AIT may be associated
with chronic urticaria (27) and rarely with immune-complex
glomerulonephritis (28).  
Clinical Manifestations 
Patients with AIT may be euthyroid, or they may have
subclinical or overt hypothyroidism depending on the severity of
the immunologic damage.  Unexplained poor linear growth is a
classical initial finding in many hypothyroid children. In some
patients, an asymptomatic goiter may be noted on routine
examination.  Occasionally, an initial thyrotoxic phase occurs due
to the discharge of preformed thyroid hormone from the damaged
gland. In this case, the picture needs to be distinguished from
hyperthyroidism due to GD.  Rarely, as noted previously, both
diseases may coexist in the same patient (Hashitoxicosis). 
The typical thyroid gland in AIT is diffusely enlarged and has a
rubbery consistency. Although the surface is classically described
as ‘pebbly’ or bosselated, occasionally asymmetric enlargement
occurs that must be distinguished from thyroid neoplasia. A
palpable lymph node superior to the isthmus (‘Delphian node’)
may be noted.
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Laboratory Evaluation
Measurement of the serum TSH concentration is the best
initial screening test for the presence of primary hypothyroidism. If
the TSH is elevated, then evaluation of the serum free thyroxine
(fT4) concentration will distinguish whether the child has
subclinical (normal fT4) or overt (low fT4) hypothyroidism. A
diagnosis of AIT is made by the demonstration of an elevated
concentration of  Tg Abs and/or TPO Abs in serum. Measurement
of TSH receptor blocking Abs should be considered in adolescent
females with severe hypothyroidism because of the persistence of
this Ab population in some patients and its association with an
increased risk of having offspring with TSH receptor blocking Ab-
induced congenital hypothyroidism. Imaging studies (thyroid
ultrasonography and/or thyroid uptake and scan) may be
performed if thyroid Ab tests are negative or if a nodule is palpable,
but are rarely necessary. Occasionally, the finding of
heterogeneous echogenicity on ultrasound examination has been
described prior to the appearance of Abs. However, the typical
picture of spotty uptake of radioactive iodine that is seen in adults
is rare in children. 
Therapy
In patients who present with severe, longstanding
hypothyroidism,  slow correction with LT4 is advisable in order to
minimize the potential development of unwanted side effects
(deterioration in school performance, short attention span,
hyperactivity, insomnia, and behavior difficulties) (29). In such
patients, the replacement dose should be increased slowly over
several weeks to months. Severely hypothyroid children should
also be observed closely for complaints of severe headache when
therapy is initiated because of the rare development of
pseudotumor cerebri. In contrast, full replacement can be initiated
at once without much risk of adverse consequences in children
with mild hypothyroidism.
Treatment of children and adolescents with subclinical
hypothyroidism (normal fT4, elevated TSH) is controversial. In
adults, particularly those > 60 years of age in whom the risk of
progression to overt hypothyroidism is significant, treatment has
been recommended whenever the serum TSH concentration is
>10 mU/L; if  TSH is in the 6-10 mU/L range, treatment on a case
by case basis is suggested (30). Long-term follow-up studies of
children with subclinical hypothyroidism due to AIT have
suggested a significant likelihood of remission. Consequently, if
there is not a strong family history of hypothyroidism and the
patient is not symptomatic, a reasonable option is to reassess
thyroid function in 6 months.  On the other hand, some initially
euthyroid patients will become hypothyroid over time. Therefore,
regular follow-up is necessary.
The typical replacement dose of LT4 in childhood is
approximately 100 µg/m2 or 4 to 6 µg/kg for children 1 to 5 years
of age, 3 to 4 µg/kg for those aged 6 to 10 years, and 2 to 3 µg/kg
for those 11 years of age and older. In patients with a goiter, a
somewhat higher LT4 dosage is used so as to keep the TSH in the
low normal range (0.3 to 1.0 mU/L in an ultrasensitive assay), and
thereby minimize its goitrogenic effect. T4 and TSH should be
measured after the child has received the recommended dosage
for at least 6-8 weeks. Once a euthyroid state has been achieved,
patients should be monitored every 6 to 12 months. Thyroid
hormone replacement is not associated with significant weight
loss in overweight children, unless the hypothyroidism is severe
(31). Treatment is usually continued indefinitely.  
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